Oxford BioDynamics Fiscal 2019 Revenues Down 24 Percent

Dec 11, 2019

|

NEW YORK — Oxford BioDynamics reported on Wednesday a 24 percent drop in revenues for its fiscal year 2019 amid a decline in revenues generated in the US.

To read the full story....

...and receive Daily News bulletins.

Already have a GenomeWeb or 360Dx account?
Login Now.

Don't have a GenomeWeb or 360Dx account?
Register for Free.

The Scan

Cost of a Visa

The Guardian reports that visa costs could prevent scientists and others from coming to the UK.

Rethinking Access Order

The Trump Administration is reconsidering its plan to issue an executive order to require federally funded research to be freely available upon publication, Times Higher Education reports.

May Have to Close

Nature News says some preprint repositories may close down due to a lack of funds to cover costs.

Nature Papers Present Way to Analyze Cancer Mutational Signatures, Explore Treatment Resistance in Lung Cancer, More

In Nature this week: framework for analyzing cancer mutational signatures, treatment resistance in small cell lung cancer followed by increased intratumoral heterogeneity, and more.

Featured White Papers

5 Risks Researchers Take by Not Prioritizing Metabolomics in Drug Development

Metabolomics: The Unexpected Key to Building Value in Drug Discovery and Development

The Keys to Harnessing the True Power of Metabolomics

AlbuVoid Enrichment & Antibody Depletion – Tackling the Challenges of Serum Proteomics Part II

Feb

27

Featured Webinar

Digital PCR Method Development for Accurate Quantification of Copy Number Variations

Since the publication of the “The Digital MIQE Guidelines: Minimum Information for Publication of Quantitative Digital PCR Experiments” (dMIQE) in 2013, there has been a large expansion of the applications of dPCR such as single nucleotide variations (SNVs) and copy number variations (CNVs) measurements associated with disease diagnostics.

Mar

18

Featured Webinar

Comparison of Genome-Wide versus Targeted cfDNA Testing for First-Line Prenatal Screening: Real-World Data

This webinar will discuss data from a recent real-world comparison study evaluating performance of two cell-free DNA methodologies as first-line prenatal screens.

Mar

31

Featured Webinar

The Role of Single-Cell Functional Biomarkers in Next-Generation Cancer Therapies

This webinar will discuss the application of single-cell proteomics and immune-imaging in adoptive cell therapy (ACT) for cancer.

Menu

Oxford BioDynamics Fiscal 2019 Revenues Down 24 Percent

To read the full story....

Breaking News

Namocell, Takara Bio, HepaTx Partner on Single-Cell Genomics for Late-Stage Liver Disease

Ancestors of Neanderthals, Denisovans Interbred With 'Superarchaic' Hominin

DNA Methylation at Certain Sites May Have Causal Effect on Lung Function, Study Finds

BC Centre for Disease Control Launches Genomic Study to Track SARS-CoV-2

FIND, WHO Collaborate on Novel Coronavirus MDx Evaluation

Lucid Diagnostics, Fred Hutchinson Cancer Research Center Ink Esophageal Cancer Biomarker Deal

The Scan

Cost of a Visa

Rethinking Access Order

May Have to Close

Nature Papers Present Way to Analyze Cancer Mutational Signatures, Explore Treatment Resistance in Lung Cancer, More

Featured White Papers

Digital PCR Method Development for Accurate Quantification of Copy Number Variations

Comparison of Genome-Wide versus Targeted cfDNA Testing for First-Line Prenatal Screening: Real-World Data

The Role of Single-Cell Functional Biomarkers in Next-Generation Cancer Therapies

Sponsorships